Type 2 diabetes is one the most common metabolic diseases, which are obviously the price to pay for lifestyle changes in most people. Dangerous in itself, this disease provokes other metabolic disorders such as obesity, and neurodegenerative diseases, such as Alzheimer's disease. Pharmacologists are very active in creating drugs for these illnesses. The design of synthetic highly active analogues of incretins, peptide hormones produced by neuroendocrine cells, is one of the most promising research areas. Glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide are the best known incretin hormones. Analogues of the first peptide have already found application in medical practice. The next step in the creation of drugs for diabetes was the development of polyagonists, which combine the properties of several different peptide hormones responsible for glucose homeostasis. The combination of the properties of incretins gives hopes for a synergism net effect. In the past few years, the creation of such coagonists has been very fast. In some cases, the results of clinical trials have already been obtained; however, they often contradict each other. Making clear this difficult situation was the main motivation for writing the present review.
incretins, glucan-like peptide-1, glucose-dependant insulintropic polypeptide, agonism, antagonism, type 2 diabetes, obesity
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.